-
Something wrong with this record ?
Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. A study by the Acute Leukemia Working Party of the EBMT
R. Swoboda, M. Labopin, S. Giebel, J. Maertens, E. Parovichnikova, J. Versluis, J. Pavlu, A. Kopinska, S. Capria, L. Raida, A. Rambaldi, D. Caillot, F. Folber, D. Nachbaur, M. Ozturk, M. Aljurf, MT. Rubio, NC. Gorin, F. Lanza, A. Nagler, M....
Language English Country England, Great Britain
Document type Journal Article
NLK
BioMedCentral
from 2001-12-01
BioMedCentral Open Access
from 2001
Directory of Open Access Journals
from 2001
Free Medical Journals
from 2001
PubMed Central
from 2001
Europe PubMed Central
from 2001
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2001-01-01
Open Access Digital Library
from 2001-01-01
Open Access Digital Library
from 2001-01-01
Medline Complete (EBSCOhost)
from 2001-01-01
Health & Medicine (ProQuest)
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
Springer Nature OA/Free Journals
from 2001-12-01
- MeSH
- Precursor Cell Lymphoblastic Leukemia-Lymphoma * therapy mortality MeSH
- Transplantation, Autologous MeSH
- Adult MeSH
- Philadelphia Chromosome MeSH
- Remission Induction MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Prognosis MeSH
- Retrospective Studies MeSH
- Neoplasm, Residual MeSH
- Hematopoietic Stem Cell Transplantation * methods MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: The role of autologous hematopoietic stem cell transplantation (AHSCT) in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-ALL) remains controversial. The aim of this retrospective study was to analyze results of AHSCT and to identify prognostic factors. METHODS: Overall, 700 patients transplanted in first complete remission between the years 1999-2020 were included. Median patient age was 31.9 years (68% male). B-cell precursor ALL (BCP-ALL) and T-cell precursor ALL (TCP-ALL) was diagnosed in 35% and 65%, respectively. Among 190 patients with available data, negative minimal residual disease (MRD) status was reported in 167 (88%) cases. RESULTS: The probabilities of overall survival (OS) and leukemia-free survival (LFS) at 2 years were 67% and 56%; relapse incidence (RI) and non-relapse mortality (NRM) were 39% and 5%, respectively. TCP-ALL was associated with lower RI (41% vs. 56%, p=0.001), higher LFS (52% vs. 38%, p=0.002) and OS (58% vs 45%, p=0.001) at 5 years when compared to BCP-ALL. In the multivariate analysis, TCP-ALL and longer interval from diagnosis do AHSCT were associated with reduced risk of relapse (HR 0.7, p=0.006 and HR=0.95, p=0.018), better LFS (HR=0.76, p=0.02 and HR=0.95, p=0.01) and OS (HR=0.75, p=0.024 and HR=0.94, p=0.013, respectively). Increasing patient age was associated with higher NRM (HR=1.49, p<0.0001), worse LFS (HR=1.1, p=0.01) and OS (HR=1.17, p=0.0001). CONCLUSIONS: Autologous hematopoietic stem cell transplantation is relatively safe option of late treatment intensification in adults with Ph- ALL. It may be a valuable option especially in patients with TCP-ALL, however it should be proved in prospective clinical trials.
Department of Haematology Imperial College Hammersmith Hospital London UK
Department of Hematology CHU Brabois Nancy France
Department of Hematology Erasmus University Medical Center Rotterdam the Netherlands
Department of Hematology Hôpital Saint Antoine Paris France
Department of Hematology University Hospital Gasthuisberg Leuven Belgium
Division of Hematology Sheba Medical Center Tel Hashomer Israel
European Society for Blood and Marrow Transplantation Paris Study Office CEREST TC Paris France
GATA BMT Center Gülhane Military Medical Academy Ankara Turkey
Hopital d'Enfants CHU de Dijon Service Hematologie Adultes Dijon France
King Faisal Specialist Hospital and Research Centre Riyadh Saudi Arabia
National Research Center for Hematology Bone Marrow Transplantation Moscow Russian Federation
Ospedale San Raffaele s r l Haematology and BMT Milano Italy
Univ La Sapienza Dip Biotecnologie Cellulari ed Ematologia Rome Italy
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25016031
- 003
- CZ-PrNML
- 005
- 20250731091443.0
- 007
- ta
- 008
- 250708s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12885-025-14126-8 $2 doi
- 035 __
- $a (PubMed)40289118
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Swoboda, Ryszard $u Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Str. Wybrzeze Armii Krajowej 15, Gliwice, 44-101, Poland. ryszard.swoboda@gliwice.nio.gov.pl
- 245 10
- $a Autologous stem cell transplantation for adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. A study by the Acute Leukemia Working Party of the EBMT / $c R. Swoboda, M. Labopin, S. Giebel, J. Maertens, E. Parovichnikova, J. Versluis, J. Pavlu, A. Kopinska, S. Capria, L. Raida, A. Rambaldi, D. Caillot, F. Folber, D. Nachbaur, M. Ozturk, M. Aljurf, MT. Rubio, NC. Gorin, F. Lanza, A. Nagler, M. Mohty, F. Ciceri
- 520 9_
- $a BACKGROUND: The role of autologous hematopoietic stem cell transplantation (AHSCT) in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph-ALL) remains controversial. The aim of this retrospective study was to analyze results of AHSCT and to identify prognostic factors. METHODS: Overall, 700 patients transplanted in first complete remission between the years 1999-2020 were included. Median patient age was 31.9 years (68% male). B-cell precursor ALL (BCP-ALL) and T-cell precursor ALL (TCP-ALL) was diagnosed in 35% and 65%, respectively. Among 190 patients with available data, negative minimal residual disease (MRD) status was reported in 167 (88%) cases. RESULTS: The probabilities of overall survival (OS) and leukemia-free survival (LFS) at 2 years were 67% and 56%; relapse incidence (RI) and non-relapse mortality (NRM) were 39% and 5%, respectively. TCP-ALL was associated with lower RI (41% vs. 56%, p=0.001), higher LFS (52% vs. 38%, p=0.002) and OS (58% vs 45%, p=0.001) at 5 years when compared to BCP-ALL. In the multivariate analysis, TCP-ALL and longer interval from diagnosis do AHSCT were associated with reduced risk of relapse (HR 0.7, p=0.006 and HR=0.95, p=0.018), better LFS (HR=0.76, p=0.02 and HR=0.95, p=0.01) and OS (HR=0.75, p=0.024 and HR=0.94, p=0.013, respectively). Increasing patient age was associated with higher NRM (HR=1.49, p<0.0001), worse LFS (HR=1.1, p=0.01) and OS (HR=1.17, p=0.0001). CONCLUSIONS: Autologous hematopoietic stem cell transplantation is relatively safe option of late treatment intensification in adults with Ph- ALL. It may be a valuable option especially in patients with TCP-ALL, however it should be proved in prospective clinical trials.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a transplantace hematopoetických kmenových buněk $x metody $7 D018380
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a autologní transplantace $7 D014182
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a filadelfský chromozom $7 D010677
- 650 12
- $a akutní lymfatická leukemie $x terapie $x mortalita $7 D054198
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a reziduální nádor $7 D018365
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Labopin, Myriam $u Department of Hematology and Cellular Therapy, National Institute of Health and Medical Research Unit UMR-S 938, Sorbonne University and St Anthony Scientific Research Center, Public Assistance Hospital of Paris, St Anthony Hospital, Paris, France $u European Society for Blood and Marrow Transplantation Paris Study Office/CEREST-TC, Paris, France
- 700 1_
- $a Giebel, Sebastian $u Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Str. Wybrzeze Armii Krajowej 15, Gliwice, 44-101, Poland
- 700 1_
- $a Maertens, Johan $u Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium
- 700 1_
- $a Parovichnikova, Elena $u National Research Center for Hematology, Bone Marrow Transplantation, Moscow, Russian Federation
- 700 1_
- $a Versluis, Jurjen $u Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands
- 700 1_
- $a Pavlu, Jiri $u Department of Haematology, Imperial College, Hammersmith Hospital, London, UK
- 700 1_
- $a Kopinska, Anna $u Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland
- 700 1_
- $a Capria, Saveria $u Univ. La Sapienza, Dip. Biotecnologie Cellulari ed Ematologia, Rome, Italy
- 700 1_
- $a Raida, Ludek $u Department of Haemato-Oncology, Olomouc University Hospital and Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
- 700 1_
- $a Rambaldi, Alessandro $u Department of Oncology and Hematology, University of Milan and Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Milan, Italy
- 700 1_
- $a Caillot, Denis $u Hopital d'Enfants, CHU de Dijon, Service Hematologie Adultes, Dijon, France
- 700 1_
- $a Folber, Frantisek $u Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital Brno, Brno, Czech Republic
- 700 1_
- $a Nachbaur, David $u Department of Internal Medicine V (Hematology and Medical Oncology), Medical University of Innsbruck, Anichstrasse 35, Innsbruck, A- 6020, Austria
- 700 1_
- $a Ozturk, Mustafa $u GATA BMT Center, Gülhane Military Medical Academy, Ankara, Turkey
- 700 1_
- $a Aljurf, Mahmoud $u King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
- 700 1_
- $a Rubio, Marie Thérèse $u Department of Hematology, CHU Brabois, Nancy, France
- 700 1_
- $a Gorin, Norbert Claude $u Department of Hematology, Hôpital Saint-Antoine, Paris, France
- 700 1_
- $a Lanza, Francesco $u Hematology Unit, University Hospital and Romagna Transplant Network, Ravenna, University of Bologna, Bologna, Italy
- 700 1_
- $a Nagler, Arnon $u Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel
- 700 1_
- $a Mohty, Mohamad $u Department of Hematology and Cellular Therapy, National Institute of Health and Medical Research Unit UMR-S 938, Sorbonne University and St Anthony Scientific Research Center, Public Assistance Hospital of Paris, St Anthony Hospital, Paris, France $u European Society for Blood and Marrow Transplantation Paris Study Office/CEREST-TC, Paris, France
- 700 1_
- $a Ciceri, Fabio $u Ospedale San Raffaele s.r.l., Haematology and BMT, Milano, Italy
- 773 0_
- $w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 25, č. 1 (2025), s. 787
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40289118 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091437 $b ABA008
- 999 __
- $a ok $b bmc $g 2366704 $s 1253156
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 25 $c 1 $d 787 $e 20250428 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
- LZP __
- $a Pubmed-20250708
